Skip to main content
  • Hydrogen Sulfide-Donor Sodium Thiosulfate Fails to Reduce Infarct Size vs. Placebo at 4 Months in STEMI Patients – GIPS-IV Trial

    Hydrogen sulfide (H2S)-donor sodium thiosulfate (STS) did not reduce infarct size versus placebo in patients presenting with ST-segment elevation myocardial infarction (STEMI) in the Phase II GIPS-IV trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details